Sky Bio-Pharma (India ) Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 14-05-2024
- Paid Up Capital ₹ 1.00 M
as on 14-05-2024
- Company Age 22 Year, 11 Months
- Last Filing with ROC 31 Mar 2017
- Revenue 542.91%
(FY 2016)
- Profit 767.37%
(FY 2016)
- Ebitda 15.01%
(FY 2016)
- Net Worth 55.95%
(FY 2016)
- Total Assets 11.68%
(FY 2016)
About Sky Bio-Pharma (India )
- CIN/LLPIN
U24110MH2002PLC134562
- Company No.
134562
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
15 Jan 2002
- Date of AGM
29 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sky Bio-Pharma (India )?
Board Members(8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinod Vyas  | Director | 15-Jan-2002 | Current |
| Durgesh Chandavarkar | Director | 15-Jan-2002 | Current |
| Vijay Vyas | Director | 16-Mar-2015 | Current |
| Dhruv Vyas | Director | 16-Mar-2015 | Current |
| Haresh Vyas | Director | 15-Jan-2002 | Current |
| Ketan Vyas | Director | 24-Dec-2002 | Current |
Financial Performance of Sky Bio-Pharma (India ).
Sky Bio-Pharma (India ) Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 542.91% increase. The company also saw a substantial improvement in profitability, with a 767.37% increase in profit. The company's net worth Soared by an impressive increase of 55.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sky Bio-Pharma (India )?
In 2017, Sky Bio-Pharma (India ) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Royal Castor Products LimitedActive 30 years 4 monthsVinod Vyas, Durgesh Chandavarkar and 1 more are mutual person
Veedol Corporation LimitedActive 103 years 2 monthsVinod Vyas and Durgesh Chandavarkar are mutual person
Astrum Healthcare Private LimitedActive 25 years 3 monthsVinod Vyas, Durgesh Chandavarkar and 5 more are mutual person
Motul India Private LimitedActive 22 years 3 daysDurgesh Chandavarkar, Dhruv Vyas and 2 more are mutual person
Tarapur Grease Industries Private LimitedActive 34 years 23 daysVinod Vyas, Durgesh Chandavarkar and 5 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sky Bio-Pharma (India )?
Unlock and access historical data on people associated with Sky Bio-Pharma (India ), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sky Bio-Pharma (India ), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sky Bio-Pharma (India )'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
